Be realistic, responsive and transparent: how to engage underperforming sites
Being realistic, responsive and transparent is key in engaging unresponsive and underperforming clinical trial sites; that was the takeaway from …
Post
-
-
Trump’s tariffs will trickle down the clinical trial chain
As President Trump’s tariff restrictions are imposed on China, the pharmaceutical industry has been deciphering how it will be impacted …
-
AbViro launches NIH-funded dengue challenge trial
A US federally funded Phase II challenge trial investigating AbViro’s sole pipeline candidate, AV1, will see 84 patients infected with …
-
Large-scale study maps cancer mortality across Latin American cities
Historical epidemiological analysis has demonstrated an association between urbanisation and growing cancer burden across the world due to factors such …
-
Palvella to expand trial of microcystic LMs treatment gel to younger subjects
Palvella Therapeutics is set to expand its 24-week Phase III SELVA trial to include subjects aged three to five years …
-
Q32 Bio halts trials amid job cuts and pivots to alopecia treatment
Q32 Bio has put a stop to a Phase II trial of its former lead renal disease candidate as it …
-
Satellos concludes MAD cohort enrolment for Phase I trial of SAT-3247
Satellos Bioscience has concluded the enrolment of subjects for all four multiple-ascending dose (MAD) cohorts for the Phase I trial …
-
BMS’ Phase II trial of CAR T cell therapy meets primary endpoint
Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of differentiation 19 (CD19)-directed …
-
Boehringer seeks approval of lung disease drug after second Phase III success
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the company …
-
Radiopharm’s imaging molecule hits mark in observational trial
Radiopharm Theranostics’ novel imaging small molecule, RAD 101, has detected brain metastases in all 22 patients enrolled in an observational …
-
Regeneron’s macular oedema therapy shows promise in Phase III trial
Regeneron Pharmaceuticals has reported positive outcomes from the Phase III QUASAR trial of Eylea HD (aflibercept) 8mg injection in treating …
-
Cyclo Therapeutics logs efficacy win in pivotal Niemann-Pick disease trial
A Phase III study examining a treatment for the rare genetic disorder Niemann-Pick disease has seen 87% of its participants, …
-
Maze Therapeutics doses first subject in Phase II AKD treatment trial
Maze Therapeutics has dosed the first subject in the Phase II HORIZON study to evaluate its oral apolipoprotein L1 (APOL1) inhibitor, …
-
Eli Lilly reports positive data from trial of Omvoh for Crohn’s disease
Eli Lilly has revealed that subjects with moderately to severely active Crohn's disease have achieved long-term clinical and endoscopic outcomes …
-
Sepsis survival: risks, realities and challenges
Sepsis is a life-threatening condition that occurs when the body’s response to infection causes widespread inflammation that damages its tissues …
